You're in the exam room. Your doctor says, "I'm going to start you on semaglutide." Great. Then comes the fork — Ozempic or Wegovy? Same active ingredient. Same manufacturer (Novo Nordisk). Same weekly injection. Different label, different dose ceiling, different insurance lane — and, depending on your plan, a difference of $400 a month out of pocket. I had this exact moment in February. Same shrug from the doctor. Same blank stare from me.

Tirzepatide has the same split. Mounjaro for type 2 diabetes. Zepbound for obesity. Eli Lilly makes both. Liraglutide, too: Victoza for diabetes, Saxenda for weight loss.

The molecule doesn't change. Everything around it does — and the box that lands in your hand decides what you pay, how high your dose can climb, and how fast the PA clears.

One molecule, two brands: the dual-label map

Three GLP-1 molecules currently carry both a diabetes and an obesity indication in the US:

Molecule	Diabetes brand	Obesity brand	Diabetes dose range	Obesity dose range
Semaglutide	Ozempic	Wegovy	0.25–2 mg/week	0.25–2.4 mg/week
Tirzepatide	Mounjaro	Zepbound	2.5–15 mg/week	2.5–15 mg/week
Liraglutide	Victoza	Saxenda	0.6–1.8 mg/day	0.6–3 mg/day

And the oral options:

Molecule	Diabetes brand	Obesity brand	Diabetes doses	Obesity doses
Oral semaglutide	Rybelsus	Oral Wegovy	3–14 mg/day	3–50 mg/day

Notice the pattern. Obesity doses go higher every time. Wegovy tops out at 2.4 mg versus Ozempic's 2 mg. Saxenda climbs to 3 mg daily versus Victoza's 1.8 mg. Oral Wegovy pushes all the way to 50 mg — Rybelsus stops at 14 mg.

The dose ceiling exists because weight loss demands more drug to keep appetite and metabolic effects in check. Diabetes management often responds at lower levels.

What actually differs beyond the label

Three things separate the diabetes brand from the obesity brand, and none of them involve the molecule itself.

The FDA indication. Ozempic is approved for type 2 diabetes with proven cardiovascular benefit. Wegovy is approved for chronic weight management in adults with BMI ≥30 (or ≥27 with at least one weight-related condition) — and, since 2024, for cardiovascular risk reduction based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events in people with obesity and established heart disease.

The dose range. Higher ceiling on the obesity side. Wegovy's ramp-up goes 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16–20 weeks. Ozempic typically tops at 1.0 mg, with a 2 mg option added later for tighter glycemic control.

The insurance pathway. This is where things get expensive.

Why does Wegovy cost more than Ozempic?

Short answer: the sticker prices differ, but the real gap is in insurance coverage.

Drug	Approximate list price/mo	Typical commercial copay	Medicare Part D
Ozempic	$900–$1,000	$25–$50 (T2D indication, usually on formulary)	Covered for T2D
Wegovy	$1,300–$1,400	$0–$500+ (depends on PA approval, plan, tier)	$50/mo from July 1, 2026
Mounjaro	$1,000–$1,100	$25–$50 (T2D)	Covered for T2D
Zepbound	$1,000–$1,100	$0–$500+ (obesity PA required)	$50/mo from July 1, 2026

Ozempic and Mounjaro slide through commercial insurance for diabetes with little friction. Most plans have them on formulary. The PA process is shorter because diabetes is a well-established indication with clear diagnostic codes.

Wegovy and Zepbound? Obesity coverage is growing but still patchy. Prior authorization is almost always required. Some plans still exclude anti-obesity medications outright. The PA paperwork is heavier — PBMs want BMI documentation, evidence of prior behavioral interventions, sometimes proof of comorbidities.

A person with a BMI of 38 and prediabetes might get Ozempic covered easily once they cross the diabetes threshold. Before that threshold? Wegovy coverage could take weeks of appeals. Same drug. Same body. Different billing code.

"I have diabetes AND obesity — which one do I get?"

This question comes up in every GLP-1 subreddit. The answer depends on what your doctor prioritizes and what your insurance will cover.

If your primary diagnosis is type 2 diabetes, your doctor will likely prescribe Ozempic or Mounjaro. Insurance covers it for that indication. You'll lose weight as a side effect — semaglutide at the 1 mg diabetes dose still produces meaningful weight loss in most people.

If your primary diagnosis is obesity and you don't have diabetes, Wegovy or Zepbound is the on-label choice. The dose goes higher. The weight-loss data is stronger at those higher doses.

If you have both? Some doctors prescribe the diabetes brand at the diabetes dose and leave it there — the weight loss happens anyway. Others push for the obesity brand at the higher dose to maximize both outcomes. Your insurance plan's formulary often makes the decision for you.

One thing worth mentioning to your doctor: if you have type 2 diabetes and a BMI over 30, you may qualify for either indication. That gives your prescriber flexibility to write whichever brand your plan covers more easily.

How much less weight do diabetes patients lose?

The clinical trials tell a consistent story: people with type 2 diabetes lose less weight on the same drug at the same dose than people without diabetes.

Semaglutide 2.4 mg (Wegovy dose):

STEP 1 (no diabetes): -14.9% body weight over 68 weeks
STEP 2 (with type 2 diabetes): -9.6% body weight over 68 weeks

Tirzepatide 15 mg (top dose):

SURMOUNT-1 (no diabetes): -20.9% body weight over 72 weeks
SURMOUNT-2 (with type 2 diabetes): -12.8% to -14.7% body weight over 72 weeks

A 5–10 percentage point gap. Not trivial. The reasons aren't fully settled, but insulin resistance, concurrent diabetes medications, and metabolic differences all likely play a role. Worth keeping in your back pocket if your sister-in-law with T2D and your coworker without ended up on the same milligram and the scale moved differently.

Does this mean the drug "works less" if you have diabetes? No. A 9.6% or 14.7% loss is still clinically meaningful, and the glycemic benefits are substantial. SURPASS trials showed tirzepatide lowering HbA1c by 2.0% to 2.3% — striking for a single agent.

But if you've seen the -20.9% headlines and you have diabetes, calibrate your expectations. The numbers are still good. They're just not the same numbers — and that's the line I wish someone had said to me out loud before I started doing math on a napkin.

Off-label Ozempic for weight loss: the gray zone

Some doctors prescribe Ozempic off-label for weight loss in patients who don't have diabetes. It's legal — doctors can prescribe FDA-approved drugs off-label. But there are catches.

Insurance rarely covers it. If the claim goes through with an obesity diagnosis code and an Ozempic script, the PBM will often reject it because Ozempic's label doesn't include obesity. You'll get a denial letter.

You'll also cap out at a lower dose. Ozempic maxes at 2 mg. Wegovy goes to 2.4 mg. That 0.4 mg matters at the top of the titration — it's the difference between the diabetes-optimized dose and the weight-optimized dose.

Cash pay for Ozempic runs $900–$1,000 a month. Wegovy is $1,300–$1,400. If you're paying out of pocket, the cost difference might push you toward Ozempic — but you're leaving dose ceiling on the table.

If a doctor offers you off-label Ozempic for weight loss and you don't have diabetes, ask two questions: "Would I get a higher dose on Wegovy?" and "Is there any chance my insurance would cover Wegovy instead?" The answer to both is usually yes.

Switching brands mid-treatment

Same molecule means no washout period — your body doesn't care what's printed on the pen.

Switching from Ozempic to Wegovy (or vice versa) is a matter of adjusting the dose. If you've been on Ozempic 1 mg and you're moving to Wegovy, your doctor might start you at Wegovy 1.7 mg (the next step up) rather than restarting the full titration from 0.25 mg. The switching medications guide has the full dose-mapping details.

Same story for Mounjaro to Zepbound. Same tirzepatide. Different pen, different label.

The usual triggers for a switch:

Insurance changes. Your plan drops one brand or adds another. Happens constantly during open enrollment season.
Indication changes. You develop diabetes and your doctor moves you to the T2D brand for easier coverage. Or your diabetes goes into remission (yes, it happens on GLP-1s) and you shift to the obesity brand for long-term weight management.
Dose ceiling. You've maxed out on Ozempic at 2 mg and your doctor wants to push to 2.4 mg on Wegovy.

If you're weighing a switch, the cost and insurance guide breaks down the coverage implications in detail.

Four real-world scenarios

Theory is nice. Here's what people deal with in practice.

Scenario 1: Commercial insurance, type 2 diabetes. Doctor prescribes Mounjaro. PBM runs it. PA takes 3–7 business days. Approved. Copay: $25 with manufacturer savings card. Monthly cost: $25. Smooth.

Scenario 2: Commercial insurance, obesity only. Doctor prescribes Zepbound. PBM flags it for PA. PA requires BMI documentation, proof of prior behavioral intervention, and sometimes a step-therapy note showing you tried something else first. Timeline: 7–21 business days. Approval rate varies wildly by plan. If approved, copay might be $50–$150 depending on tier. If denied, you appeal — and about 50% of first-round denials get overturned with proper documentation.

Scenario 3: Medicare, starting July 2026. Medicare Part D will cover Wegovy and Zepbound at $50/month starting July 1, 2026. This is new. Before this, Medicare explicitly excluded anti-obesity medications. The Wegovy cardiovascular indication created a legal opening, and Congress expanded it. If you're on Medicare and your doctor says "we can't cover weight-loss drugs," that information is outdated as of July.

Scenario 4: Cash pay, no insurance. Foundayo (orforglipron) at $149/month is the new floor. It's oral — no injection. FDA-approved April 2026 for obesity. LillyDirect sells it direct. For injectable options, LillyDirect offers Zepbound at $549–$599/month cash. Novo Nordisk's NovoCare program has Wegovy savings cards that can knock off up to $500/month — but only for commercially insured patients.

What Foundayo changes about this equation

Foundayo (orforglipron) reshapes the conversation. At $149/month with no injection required, it sidesteps the two biggest barriers to GLP-1 access: cost and needle aversion.

It's approved for obesity only — not diabetes (as of May 2026). So it doesn't slot into the dual-indication pattern the same way. But for someone who's been denied Wegovy coverage and can't afford $1,300/month, $149 is a different calculus entirely.

The weight-loss data isn't as strong as injectable semaglutide or tirzepatide at max doses. But it's oral, it's affordable, and it's on the market now.

Before you fill the prescription

Whether your doctor writes Ozempic or Wegovy, Mounjaro or Zepbound — do three things before the script hits the pharmacy.

Check your formulary. Call the number on your insurance card. Ask: "Is [drug name] on formulary? What tier? Does it require prior authorization?" Write down the rep's name and reference number.

Ask about both brands. If you have type 2 diabetes and obesity, ask your doctor: "Which brand gives me the easiest coverage path with my plan?" Sometimes the T2D brand covers faster even if the obesity brand would give a higher dose. Let your doctor weigh that tradeoff.

Know the cash-pay floor. If insurance falls through, Foundayo at $149/month is real. LillyDirect Zepbound at ~$550/month is real. These aren't discount-card gimmicks — they're manufacturer direct pricing. GoodRx can sometimes beat these for older drugs like generic liraglutide.

Questions to bring to your next appointment

If you're seeing your doctor about GLP-1 options, these are the ones that move the conversation forward:

"Do I qualify for a diabetes indication, an obesity indication, or both? How does that change what you'd prescribe?"
"Which brand is on my plan's formulary — the diabetes version or the obesity version?"
"If we start with the diabetes brand, can we revisit switching to the obesity brand later for the higher dose?"
"What's the PA timeline with my insurance? Do you do peer-to-peer reviews if it gets denied?"
"Would Foundayo make sense for me, or is there a clinical reason to go with an injectable?"

The semaglutide vs tirzepatide comparison can help you think through the molecule choice before that conversation.

Same molecule, very different experience

Ozempic and Wegovy are the same drug. Mounjaro and Zepbound are the same drug. That part's simple. Everything else — the dose your doctor can prescribe, the price you pay, how long approval takes, whether Medicare covers it — comes down to which label is on the box.

The system isn't intuitive. Once you know the dual-label map, you can ask better questions, navigate the PA process with less frustration, and stop overpaying for a molecule that comes in a cheaper package under a different name.

That's worth knowing before the prescription gets written, not after. And one thing that should be obvious but bears saying: if you don't have diabetes, don't try to game a diabetes-label drug by faking a diagnosis. Insurance fraud is a federal offense, and your doctor won't go along with it. Every GLP-1 here is a prescription medication — the final call on which one, which dose, and which indication belongs to your prescriber. Ask the questions, do the homework, then let them do their job.